

Jennifer Byrne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6884085/publications.pdf>

Version: 2024-02-01

79
papers

2,845
citations

279798

23
h-index

175258

52
g-index

79
all docs

79
docs citations

79
times ranked

3225
citing authors

#	ARTICLE	IF	CITATIONS
1	Upfront unrelated donor hematopoietic stem cell transplantation in patients with idiopathic aplastic anemia: A retrospective study of the Severe Aplastic Anemia Working Party of European Bone Marrow Transplantation. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	7
2	The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, , .	2.5	1
3	Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. <i>Lancet Haematology</i> , 2022, 9, e121-e132.	4.6	21
4	Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT. <i>British Journal of Haematology</i> , 2022, , .	2.5	0
5	Comparison of fludarabine+melphalan and fludarabine+treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2022, 57, 1269-1276.	2.4	6
6	Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2021, 56, 529-531.	2.4	1
7	Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 481-491.	2.4	10
8	Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 768-778.	1.6	95
9	Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP+EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1563-1572.	2.4	1
10	Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. <i>British Journal of Haematology</i> , 2021, 192, 62-74.	2.5	18
11	Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2021, 138, 3954-3954.	1.4	0
12	Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service. <i>Blood</i> , 2021, 138, 1254-1254.	1.4	2
13	Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program. <i>Blood</i> , 2021, 138, 1942-1942.	1.4	0
14	Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. <i>Leukemia</i> , 2020, 34, 87-99.	7.2	25
15	Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT. <i>Journal of Neurology</i> , 2020, 267, 430-439.	3.6	13
16	A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 191, 171-193.	2.5	38
17	Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation—a retrospective study by the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 1560-1569.	2.4	16
18	A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. <i>Leukemia</i> , 2020, 34, 1775-1786.	7.2	49

#	ARTICLE	IF	CITATIONS
19	Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. Bone Marrow Transplantation, 2020, 55, 1975-1984.	2.4	8
20	Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. Bone Marrow Transplantation, 2020, 55, 1840-1843.	2.4	3
21	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. Biology of Blood and Marrow Transplantation, 2019, 25, 2008-2016.	2.0	20
22	De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematology, 2019, 6, e375-e383.	4.6	129
23	Outcome of allografting for AML-CR2 is equivalent across BSBMT and EBMT and is associated with encouraging OS and DFS across all age groups. Bone Marrow Transplantation, 2019, 54, 1151-1154.	2.4	0
24	Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome: A Large Series from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2019, 134, 2053-2053.	1.4	0
25	Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 903-915.	3.3	2
26	High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica, 2017, 102, 160-167.	3.5	49
27	Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2017, 177, 759-765.	2.5	38
28	De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematology, 2017, 4, e310-e316.	4.6	97
29	The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomised, double-blind, double-dummy, symptom study (RELIEF). British Journal of Haematology, 2017, 176, 76-85.	2.5	69
30	Incidence and management of hepatic severe veno-occlusive disease in 273 patients in a single centre with defibrotide. Bone Marrow Transplantation, 2016, 51, 1262-1264.	2.4	6
31	Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial. Biology of Blood and Marrow Transplantation, 2016, 22, 385-390.	2.0	151
32	Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: A British Society of Blood and Marrow Transplantation study. Bone Marrow Transplantation, 2015, 50, 82-86.	2.4	9
33	Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia. Blood, 2015, 126, 4024-4024.	1.4	7
34	Extracorporeal Photopheresis As Second Line Therapy for Steroid Refractory Acute Gvhd: Retrospective Study of Long-Term Outcomes. Blood, 2015, 126, 1944-1944.	1.4	0
35	Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma Study results. British Journal of Haematology, 2014, 166, 109-117.	2.5	28
36	Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma. Leukemia Research, 2014, 38, 737-743.	0.8	7

#	ARTICLE	IF	CITATIONS
37	The acute impact of a hematopoietic allograft on lung function and inflammation: a prospective observational study. <i>BMC Pulmonary Medicine</i> , 2013, 13, 2.	2.0	4
38	Pepperpot or not?. <i>British Journal of Haematology</i> , 2013, 162, 431-431.	2.5	0
39	BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6512-6512.	1.6	3
40	Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8015-8015.	1.6	1
41	Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. <i>Lancet Oncology</i> , The, 2011, 12, 743-752.	10.7	151
42	Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. <i>Haematologica</i> , 2011, 96, 1779-1782.	3.5	20
43	Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant <i>in vivo</i> Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2011, 153, 244-252.	2.5	18
44	Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. <i>Blood</i> , 2011, 118, 1231-1238.	1.4	179
45	Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission. <i>Annals of Hematology</i> , 2010, 89, 505-512.	1.8	39
46	First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Tj ETQq0 0 0 rBT /Overlock 10 Tf	18.7	505
47	Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab. <i>Bone Marrow Transplantation</i> , 2008, 42, 281-282.	2.4	8
48	Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. <i>British Journal of Haematology</i> , 2008, 141, 235-243.	2.5	44
49	Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. <i>British Journal of Haematology</i> , 2008, 142, 318-320.	2.5	8
50	The Safety, Pharmacokinetics and Pharmacodynamics of KW-2478, a Novel Hsp90 Antagonist, in Patients with B-Cell Malignancies: A First-in-Man, Phase I, Multicentre, Open-Label, Dose Escalation Study. <i>Blood</i> , 2008, 112, 2777-2777.	1.4	7
51	Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. <i>Blood</i> , 2007, 110, 4614-4617.	1.4	101
52	The Impact of Chimerism Patterns and Predonor Leukocyte Infusion Lymphopenia on Survival following T Cell-Depleted Reduced Intensity Conditioned Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 550-559.	2.0	24
53	Long-Term Outcome of Unrelated Donor Transplantation for AML Using Myeloablative Conditioning Incorporating Pretransplant Alemtuzumab. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 724-733.	2.0	14
54	High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma. <i>Leukemia Research</i> , 2007, 31, 1063-1068.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Ifosfamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. <i>British Journal of Haematology</i> , 2007, 136, 752-761.	2.5	19
56	Expert radiological review of skeletal surveys identifies additional abnormalities in 23% of cases: further evidence for the value of myeloma multi-disciplinary teams in the accurate staging and treatment of myeloma patients. <i>British Journal of Haematology</i> , 2007, 137, 172-173.	2.5	11
57	The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study. <i>British Journal of Haematology</i> , 2006, 134, 385-390.	2.5	55
58	Low Pre-DLI Lymphocytes Counts Are Predictive of Good Disease Responses in Patients with Mixed Chimerism Following Campath-Containing Reduced Intensity Transplants.. <i>Blood</i> , 2006, 108, 261-261.	1.4	0
59	Treatment of Enteropathy Associated T Cell Lymphoma with Combination Chemotherapy Followed by Autologous Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 5424-5424.	1.4	0
60	Low dose erythropoietin is effective in reducing transfusion requirements following allogeneic HSCT. <i>Transfusion Medicine</i> , 2005, 15, 475-480.	1.1	4
61	Reduced Intensity Allogeneic Transplantation Using BEAM-Alemtuzumab in Patients with Lymphoid Malignancy: Long Term Results and Impact of Intervention with DLI.. <i>Blood</i> , 2005, 106, 2890-2890.	1.4	9
62	Single HLA Allele Mismatches Are Well Tolerated in the Recipients of T Cell Depleted Reduced Intensity Conditioned Transplants from Unrelated Donors.. <i>Blood</i> , 2005, 106, 2895-2895.	1.4	1
63	Converting Mixed Chimerism to Full Donor Chimerism in Recipients of Campath-Containing Reduced Intensity Transplants Reduces the Relapse Risk and Results in Significantly Improved Survival Compared to Those with Persistent Full Donor Chimerism.. <i>Blood</i> , 2005, 106, 2026-2026.	1.4	6
64	Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. <i>British Journal of Haematology</i> , 2004, 126, 63-71.	2.5	35
65	BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. <i>Blood</i> , 2004, 103, 428-434.	1.4	171
66	Combination Chemotherapy with Cyclophosphamide, Thalidomide and Dexamethasone Achieves a High Response Rate in Patients with Newly Diagnosed, VAD-Refractory and Relapsed Myeloma.. <i>Blood</i> , 2004, 104, 1499-1499.	1.4	5
67	High Response Rate to DLI Based Strategies for the Treatment of Refractory Disease/Relapse Following Allogeneic HSCT for Lymphoproliferative Disease.. <i>Blood</i> , 2004, 104, 1653-1653.	1.4	0
68	Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. <i>British Journal of Haematology</i> , 2003, 123, 479-483.	2.5	21
69	Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Leukemia</i> , 2003, 17, 1707-1712.	7.2	101
70	Chromosomal abnormalities in Ph- cells of patients on imatinib. <i>Blood</i> , 2003, 102, 2700-2701.	1.4	22
71	Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. <i>Blood</i> , 2002, 99, 2586-2591.	1.4	137
72	CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. <i>Blood</i> , 2002, 100, 3843-3843.	1.4	26

#	ARTICLE	IF	CITATIONS
73	Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. British Journal of Haematology, 2002, 119, 144-154.	2.5	79
74	Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM+“CAMPATH (±) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 2001, 3, 203-210.	0.7	24
75	Allogeneic Haemopoietic Stem Cell Transplantation for Multiple Myeloma or Plasma Cell Leukaemia Using Fractionated Total Body Radiation and High-dose Melphalan Conditioning. Acta OncolÁ³gica, 2000, 39, 837-841.	1.8	21
76	Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkinâ€™s lymphomas and Hodgkinâ€™s disease. Bone Marrow Transplantation, 1999, 24, 715-722.	2.4	25
77	Heparin-induced thrombocytopenia (HIT) and thrombosis syndrome in a haemodialysis-dependent patient with systemic vasculitis. Nephrology Dialysis Transplantation, 1998, 13, 3226-3229.	0.7	16
78	Haemopoietic Growth Factors. , 0, , 303-317.		0
79	Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 0, ,	2.4	1